期刊
TRANSPLANTATION AND CELLULAR THERAPY
卷 28, 期 6, 页码 284-293出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtct.2022.03.019
关键词
Multiple myeloma; Autologous transplantation; Allogeneic transplantation; Cellular therapy; CAR T-cells; Consensus
Therapeutic options in multiple myeloma have changed dramatically in the past decade. A panel of experts formulated clinical practice recommendations for the role, timing, and sequencing of autologous and allogeneic hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy. The panel endorsed the use of auto-HCT consolidation for newly diagnosed patients and recommended its use in the first relapse for patients not undergoing upfront auto-HCT.
Over the past decade, therapeutic options in multiple myeloma (MM) have changed dramatically. Given the unprecedented efficacy of novel agents, the role of hematopoietic cell transplantation (HCT) in MM remains under scrutiny. Rapid advances in myeloma immunotherapy including the recent approval of chimeric antigen receptor (CAR) T-cell therapy will impact the MM therapeutic landscape. The American Society for Transplantation and Cellular Therapy convened an expert panel to formulate clinical practice recommendations for role, timing, and sequencing of autologous (auto-HCT), allogeneic (allo-HCT) and CAR T-cell therapy for patients with newly diag-nosed (NDMM) and relapsed/refractory MM (RRMM). The RAND-modified Delphi method was used to generate consensus statements. Twenty consensus statements were generated. The panel endorsed continued use of auto-HCT consolidation for patients with NDMM as a standard-of-care option, whereas in the front line allo-HCT and CAR-T were not recommended outside the setting of clinical trial. For patients not undergoing auto-HCT upfront, the panel recommended its use in first relapse. Lenalidomide as a single agent was recommended for maintenance especially for standard risk patients. In the RRMM setting, the panel recommended the use of CAR-T in patients with 4 or more prior lines of therapy. The panel encouraged allo-HCT in RRMM setting only in the context of clinical trial. The panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MM. (c) 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据